Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07730541) titled 'Hyperpolarized 13C-MRI and Radiomics in Rectal Cancer' on July 23.
Study Type: Observational
Primary Sponsor: Chang Gung Memorial Hospital
Condition:
Neoadjuvant Chemoradiotherapy
Intervention:
Drug: Hyperpolarized 13C-MRI (HP 13C-MRI)
Recruitment Status: Recruiting
Date of First Enrollment: June 1, 2026
Target Sample Size: 30
Countries of Recruitment:
Taiwan
To know more, visit https://clinicaltrials.gov/study/NCT07730541
Disclaimer: Curated by HT Syndication....